Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management
暂无分享,去创建一个
F. Braiteh | R. Moss | G. Khan | M. Saltzman
[1] M. Lacouture,et al. Regorafenib-associated hand–foot skin reaction: practical advice on diagnosis, prevention, and management , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] V. Grünwald,et al. [Pharmacotherapy of solid tumors. New hopes and frustrations]. , 2014, Der Internist.
[3] R. Strausberg,et al. Mutational analysis of genes coding for cell surface proteins in colorectal cancer cell lines reveal novel altered pathways, druggable mutations and mutated epitopes for targeted therapy , 2014, Oncotarget.
[4] K. Bencardino,et al. Regorafenib in metastatic colorectal cancer , 2014, Expert review of anticancer therapy.
[5] J. Hurley,et al. The molecular genetics of colorectal cancer , 2013, Frontline Gastroenterology.
[6] M. Ychou,et al. Time course of regorafenib-associated adverse events in the phase III CORRECT study , 2013 .
[7] Yeul-Hong Kim,et al. Regorafenib for metastatic colorectal cancer , 2013, The Lancet.
[8] A. Kilcoyne,et al. Clinical study report , 2013 .
[9] D. Sargent,et al. Time course of regorafenib-associated adverse events in the phase III CORRECT study. , 2013 .
[10] D. Sargent,et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.
[11] G. Bjarnason,et al. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. , 2012, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[12] J. Schellens,et al. Concise drug review: pazopanib and axitinib. , 2012, The oncologist.
[13] Steven J. M. Jones,et al. Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.
[14] S. Ye,et al. A randomized controlled phase II study of the prophylactic effect of urea-based cream on the hand-foot skin reaction associated with sorafenib in advanced hepatocellular carcinoma. , 2012 .
[15] Daniel J. Sargent,et al. Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC) , 2012 .
[16] C. Eng,et al. The Current State of Targeted Agents in Rectal Cancer , 2012, International journal of surgical oncology.
[17] M Büchert,et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study , 2012, British Journal of Cancer.
[18] Martin Büchert,et al. A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors , 2012, Clinical Cancer Research.
[19] D. Zopf,et al. Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity , 2011, International journal of cancer.
[20] R. Riechelmann,et al. Cancer-related fatigue: a practical review. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] M. Fishman,et al. Experience with sorafenib and adverse event management. , 2011, Critical reviews in oncology/hematology.
[22] M. Maitland,et al. Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors , 2010, Journal of the National Cancer Institute.
[23] W. Voigt,et al. Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management , 2010, Therapeutic advances in medical oncology.
[24] M. Choti,et al. NCCN Clinical Practice Guidelines in Oncology: colon cancer. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.
[25] J. Soria,et al. Review Management of Hypertension in Angiogenesis Inhibitor-treated Patients , 2022 .
[26] William Lee,et al. Tie2 in Tumor Endothelial Signaling and Survival: Implications for Antiangiogenic Therapy , 2009, Molecular Cancer Research.
[27] B. Rini,et al. Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma , 2009, OncoTargets and therapy.
[28] H. Kong,et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. , 2008, The oncologist.
[29] C. Porta,et al. Uncovering Pandora’s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib , 2007, Clinical and Experimental Medicine.
[30] L. Wood. Managing the side effects of sorafenib and sunitinib , 2006 .
[31] M. Grace,et al. Hazard Ratio in Clinical Trials , 2004, Antimicrobial Agents and Chemotherapy.
[32] J. Ajani,et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Daniel W. Jones,et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.
[34] Roger T. Anderson,et al. Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors , 2010 .
[35] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.